Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II GS-IMRT trial in borderline resectable pancreatic cancer
jRCTs041220150Phase 2Recruiting
- Sponsor
- Mie University
- Start
- Jun 2023
- Modality
- Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and tegafur + gimeracil + oteracil in pancreatic adenocarcinoma (PDAC), sponsored by Mie University. Primary endpoint: Histological response in resected specimens. Started Jun 2023; status: recruiting.
02
Drugs
gemcitabinetegafur + gimeracil + oteracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs041220150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220150.